Pharmafile Logo
Pharmafocus logo
Advanced Search

ofatumumab

Showing 8 posts of 8 posts found.

shutterstock_159488225

Genmab & Novartis’ ofatumumab tops Sanofi’s Aubagio in relapsing multiple sclerosis

August 30, 2019
Medical Communications, Research and Development Genmab, Novartis, multiple sclerosis, ofatumumab, pharma

Genmab and Novartis have revealed positive new data from two Phase 3 studies of its monthly subcutaneous formulation of ofatumumab …

News
clinical_trial_4

Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration

June 2, 2016
Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III

Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …

News
Arzerra

Arzerra approved by US FDA for leukaemia

January 20, 2016
Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application

The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …

News
Arzerra

Genmab pulls plug on Phase III Arzerra trial

November 24, 2015
Manufacturing and Production, Research and Development Arzerra, Genmab, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma, ofatumumab, phase III, phase III failure

Genmab has stopped a Phase III study of its CD20-directed monoclonal antibody Arzerra, after it was shown to be unlikely …

News
novartis

Novartis buys rights to GSK MS drug for up to $1 billion

August 21, 2015
Medical Communications, Research and Development, Sales and Marketing GlaxoSmithKline, Novartis, multiple sclerosis, ofatumumab

Novartis has added to its burgeoning multiple sclerosis portfolio with the $300 million acquisition of all outstanding rights to GlaxoSmithKline’s …

News
arzerra image

Trial results back NICE decision on Novartis cancer drug

April 15, 2015
Sales and Marketing Arzerra, Cancer, NHS, NICE, chemo, chlorambucil, fludarabine, leukaemia, ofatumumab

Treatment with Arzerra improves survival in people with chronic lymphocytic leukaemia (CLL) according to study results that back NICE’s decision …

News
GSK image

GSK settles cancer patent dispute

March 28, 2012
Research and Development, Sales and Marketing GSK, Genmab, Roche, ofatumumab, patents

GlaxoSmithKline has settled a long-running patent dispute over its cancer treatment ofatumumab.  The US patents, which relate to recombinant antibody …

News

GSK switches to subcutaneous route for antibody

September 16, 2010
Research and Development Arzerra, Genmab, GlaxoSmithKline, ofatumumab

GlaxoSmithKline says it will switch development of a new antibody treatment to a subcutaneous injection, to make it more commercially …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026